{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:39:18Z","timestamp":1788485958883,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40120-023-00544-y","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T11:02:22Z","timestamp":1695639742000},"page":"2079-2099","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Experience of Daily Life with Generalized Myasthenia Gravis: A Qualitative Investigation and Assessment of Instrument Content Validity"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7095-0106","authenticated-orcid":false,"given":"Christopher A.","family":"Hartford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Karantzoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Guillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Phinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly L.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla E.","family":"Negron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti M.","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Rofail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,25]]},"reference":[{"key":"544_CR1","unstructured":"Howard JF Jr. Clinical overview of MG. 2015. https:\/\/myasthenia.org\/Professionals\/Clinical-Overview-of-MG. Accessed Oct 1, 2022."},{"issue":"1","key":"544_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.","journal-title":"Nat Rev Dis Primers"},{"issue":"26","key":"544_CR3","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375(26):2570\u201381.","journal-title":"N Engl J Med"},{"issue":"3","key":"544_CR4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"issue":"5","key":"544_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098089","volume":"9","author":"C Barnett","year":"2014","unstructured":"Barnett C, Bril V, Kapral M, et al. A conceptual framework for evaluating impairments in myasthenia gravis. PLoS ONE. 2014;9(5):e98089.","journal-title":"PLoS ONE"},{"issue":"2","key":"544_CR6","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.1097\/JNN.0b013e31828291a6","volume":"45","author":"YT Chen","year":"2013","unstructured":"Chen YT, Shih FJ, Hayter M, et al. Experiences of living with myasthenia gravis: a qualitative study with Taiwanese people. J Neurosci Nurs. 2013;45(2):E3\u201310.","journal-title":"J Neurosci Nurs"},{"issue":"7","key":"544_CR7","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3109\/09638288.2013.804591","volume":"36","author":"A Raggi","year":"2014","unstructured":"Raggi A, Schiavolin S, Leonardi M, et al. Development of the MG-DIS: an ICF-based disability assessment instrument for myasthenia gravis. Disabil Rehabil. 2014;36(7):546\u201355.","journal-title":"Disabil Rehabil"},{"issue":"4","key":"544_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3109\/01676830.2014.904375","volume":"33","author":"HS Richards","year":"2014","unstructured":"Richards HS, Jenkinson E, Rumsey N, et al. The psychosocial impact of ptosis as a symptom of myasthenia gravis: a qualitative study. Orbit. 2014;33(4):263\u20139.","journal-title":"Orbit"},{"key":"544_CR9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3389\/fneur.2020.00604","volume":"11","author":"ME Farrugia","year":"2020","unstructured":"Farrugia ME, Goodfellow JA. A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature. Front Neurol. 2020;11:604.","journal-title":"Front Neurol"},{"issue":"9","key":"544_CR10","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1212\/WNL.0000000000002971","volume":"87","author":"C Barnett","year":"2016","unstructured":"Barnett C, Bril V, Kapral M, et al. Development and validation of the myasthenia gravis impairment index. Neurology. 2016;87(9):879\u201386.","journal-title":"Neurology"},{"issue":"1","key":"544_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1468-1331.2012.03713.x","volume":"20","author":"C Kabasawa","year":"2013","unstructured":"Kabasawa C, Shimizu Y, Suzuki S, et al. Taste disorders in myasthenia gravis: a multicenter cooperative study. Eur J Neurol. 2013;20(1):205\u20137.","journal-title":"Eur J Neurol"},{"issue":"1","key":"544_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40120-022-00408-x","volume":"12","author":"K Jackson","year":"2023","unstructured":"Jackson K, Parthan A, Lauher-Charest M, et al. Understanding the symptom burden and impact of myasthenia gravis from the patient\u2019s perspective: a qualitative study. Neurol Ther. 2023;12(1):107\u201328.","journal-title":"Neurol Ther"},{"key":"544_CR13","unstructured":"US Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input. Guidance for industry, Food and Drug Administration staff, and other stakeholders. 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients. Accessed Jan 11, 2023."},{"key":"544_CR14","unstructured":"US Food and Drug Administration. The 21st Century Cures Act. 2016. https:\/\/www.fda.gov\/regulatory-information\/selected-amendments-fdc-act\/21st-century-cures-act. Accessed Jan 11, 2023,"},{"key":"544_CR15","unstructured":"US Food and Drug Administration. Patient-focused drug development: methods to identify what is important to patients. Guidance for industry, Food and Drug Administration staff, and other stakeholders. 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients. Accessed Jan 11, 2023."},{"key":"544_CR16","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.2147\/DDDT.S49935","volume":"8","author":"O Ciani","year":"2014","unstructured":"Ciani O, Jommi C. The role of health technology assessment bodies in shaping drug development. Drug Des Dev Ther. 2014;8:2273\u201381.","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"544_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12913-023-09173-5","volume":"23","author":"E De Sutter","year":"2023","unstructured":"De Sutter E, Borry P, Huys I, et al. Informing a European guidance framework on electronic informed consent in clinical research: a qualitative study. BMC Health Serv Res. 2023;23(1):181.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"544_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13023-022-02557-6","volume":"18","author":"RR Yang","year":"2023","unstructured":"Yang RR. A patient advocating for transparent science in rare disease research. Orphanet J Rare Dis. 2023;18(1):14.","journal-title":"Orphanet J Rare Dis"},{"key":"544_CR19","volume-title":"Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products","author":"Committee for Medicinal Products for Human Use","year":"2005","unstructured":"Committee for Medicinal Products for Human Use. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. London: European Medicines Agency; 2005."},{"key":"544_CR20","doi-asserted-by":"crossref","unstructured":"US Department of Health and Human Services FDA Center for Drug Evaluation and Research, US Department of Health and Human Services FDA Center for Biologics Evaluation and Research, US Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4(1):79.","DOI":"10.1186\/1477-7525-4-79"},{"key":"544_CR21","unstructured":"US Food and Drug Administration. Guidance document: Patient-focused drug development: Selecting, developing, or modifying fit-for-purpose clinical outcome assessments. 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome. Accessed Oct 1, 2022."},{"issue":"7","key":"544_CR22","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, et al. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487\u20139.","journal-title":"Neurology"},{"key":"544_CR23","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","volume":"841","author":"RJ Barohn","year":"1998","unstructured":"Barohn RJ, McIntire D, Herbelin L, et al. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998;841:769\u201372.","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"544_CR24","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/mus.21185","volume":"38","author":"TM Burns","year":"2008","unstructured":"Burns TM, Conaway MR, Cutter GR, et al. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve. 2008;38(6):1553\u201362.","journal-title":"Muscle Nerve"},{"issue":"8","key":"544_CR25","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1\u2014eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967\u201377.","journal-title":"Value Health"},{"issue":"8","key":"544_CR26","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2\u2014assessing respondent understanding. Value Health. 2011;14(8):978\u201388.","journal-title":"Value Health"},{"issue":"1","key":"544_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16\u201323.","journal-title":"Neurology"},{"key":"544_CR28","volume-title":"Analyzing qualitative data","author":"A Bryman","year":"1994","unstructured":"Bryman A, Burgess B. Analyzing qualitative data. 1st ed. London: Routledge; 1994.","edition":"1"},{"issue":"2","key":"544_CR29","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1098214005283748","volume":"27","author":"DR Thomas","year":"2006","unstructured":"Thomas DR. A general inductive approach for analyzing qualitative evaluation data. Am J Eval. 2006;27(2):237\u201346.","journal-title":"Am J Eval"},{"issue":"2","key":"544_CR30","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40120-021-00285-w","volume":"10","author":"N Law","year":"2021","unstructured":"Law N, Davio K, Blunck M, et al. The lived experience of myasthenia gravis: a patient-led analysis. Neurol Ther. 2021;10(2):1103\u201325.","journal-title":"Neurol Ther"},{"issue":"8","key":"544_CR31","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.nmd.2020.06.010","volume":"30","author":"AM Ruiter","year":"2020","unstructured":"Ruiter AM, Verschuuren J, Tannemaat MR. Fatigue in patients with myasthenia gravis. A systematic review of the literature. Neuromuscul Disord. 2020;30(8):631\u20139.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"544_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s13023-021-02064-0","volume":"16","author":"S Cleanthous","year":"2021","unstructured":"Cleanthous S, Mork AC, Regnault A, et al. Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease. Orphanet J Rare Dis. 2021;16(1):457.","journal-title":"Orphanet J Rare Dis"},{"key":"544_CR33","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207278","author":"JT Guptill","year":"2023","unstructured":"Guptill JT, Benatar M, Granit V, et al. Addressing outcome measure variability in myasthenia gravis clinical trials. Neurology. 2023. https:\/\/doi.org\/10.1212\/WNL.0000000000207278.","journal-title":"Neurology"},{"key":"544_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00464-x","author":"A Regnault","year":"2023","unstructured":"Regnault A, Morel T, de la Loge C, et al. Measuring overall severity of myasthenia gravis (MG): evidence for the added value of the MG symptoms PRO. Neurol Ther. 2023. https:\/\/doi.org\/10.1007\/s40120-023-00464-x.","journal-title":"Neurol Ther"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00544-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00544-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00544-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T05:32:52Z","timestamp":1699335172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00544-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,25]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["544"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00544-y","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,25]]},"assertion":[{"value":"17 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Christopher Hartford, Steven Sherman, and Diana Rofail are all employees of and stockholders in Regeneron Pharmaceuticals, Inc. Stella Karantzoulis, Isabelle Guillemin, Michael Phinney, Kimberly Kelly, and Kayla Negron were all employees of IQVIA at the time of study conduct. Shruti Raja is a consultant to Regeneron Pharmaceuticals, Inc. The authors received no honoraria related to the development of this publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and are consistent with Good Clinical Practice and applicable regulatory requirements. The study was reviewed and approved by the WCG institutional review board (IRB), IRB number 20213567. The research protocol, interview guides, all documents associated with patient interviews, and all clinician communication documents were also reviewed and approved by WCG IRB. Informed, written consent was obtained electronically from each participant prior to their enrollment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Guidelines"}}]}}